Saturation genome editing of BRCA1 across cell types improves interpretation of variant pathogenicity
Gene / mechanism
BRCA1
BRCA1 single-nucleotide variants assessed by saturation genome editing; hypomorphic variants with cell-type-dependent effects
Summary
Over half of reported single-nucleotide variants in BRCA1 lack a definitive clinical interpretation, and the consistency of their effects across cell types had been little explored. The authors performed saturation genome editing (SGE) of BRCA1 in HAP1 cells, scoring 4,113 previously unassayed variants, and developed an SGE assay in human mammary epithelial cells (HMECs) to compare effects across cell lines, drug treatments and genetic backgrounds. In total, 538 variants impair gene function through distinct mechanisms, and HAP1 function scores discriminate known pathogenic from benign variants with near-perfect accuracy. Yet nearly half of HAP1 loss-of-function variants score neutrally in HMECs: these discordant variants are hypomorphic and confer intermediate cancer risk.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
A first SGE of BRCA1 was published in Nature in 2018; this work extends its coverage and, above all, shows that a score obtained in a single cell line can overstate a variant's effect. For the laboratory, these scores provide functional evidence that can be used directly when interpreting BRCA1 variants of uncertain significance, a gene already captured by exome and genome sequencing. The category of hypomorphic variants with intermediate risk, however, raises a genetic counselling question that the usual pathogenicity classes do not resolve.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 3/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 0/1 · Publication status: 1/1 → Total: 7/10
Keywords
More articles on BRCA1
Every Wednesday · Annotated selection · Free · Unsubscribe anytime